Sale

CAR T-Cell Therapy Market

Global CAR T-Cell Therapy Market Size, Share, Forecast: By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleuce, Idecabtagene Vicleucel, Ciltacabtegene Autoleucel, Others; By Antigen: CD19, BCMA, HER2, GD2, CD22, Others; By Application; Regional Analysis; Supplier Landscape; 2024-2032

Global CAR T-Cell Therapy Market Outlook

The global CAR T-cell therapy market size was valued at USD 2.5 billion in 2023, driven by the rising prevalence of cancer across the globe. The market is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to rise from USD 2.9 billion in 2024 to USD 9.0 billion by 2032.

 

Global CAR T-Cell Therapy Market Overview

Chimeric antigen receptor (CAR) T-cell therapy is a method of modifying the immune cells, also known as T-cells to fight and destroy cancerous cells in the body. The market demand is majorly driven by growing incidence of cancer. CAR T-cell therapy has also garnered substantial excitement amongst researchers owing to ability to eradicate advanced leukaemia and lymphomas. The market is further propelled by rising investments on CAR T-cell related research and development and subsequent growth in number of FDA approvals for new therapies.

 

car t-cell therapy market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Incidence of Cancer Cases

In 2023, cancer is expected to affect approximately 2 million people in the United States. Non-Hodgkin Lymphoma and Leukaemia are one of the top 12 cancers expected to affect around 80,550 and 59,610 patients respectively. Out of the two, leukaemia is anticipated to cause 23,710 deaths while Non-Hodgkin Lymphoma may lead to 20,180 deaths. Hence, the CAR T-cell therapy market demand is projected to surge in upcoming years, as researchers aim at maximising its application to offer improved patient solutions.

 

Rising Collaborations Between Key Players

In December 2023, AbelZeta and AstraZeneca entered a partnership to develop the autologous, armoured GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, C-CAR031, designed to treat hepatocellular carcinoma (HCC). C-CAR031 leverages AstraZeneca’s growth factor-beta receptor II (TGFβRII) dominant negative armouring discovery platform along with AbelZeta’s cell therapies. The project pipeline also constitutes tumour-infiltrating lymphocyte therapies. Together, the companies envision at bringing effective and innovative therapeutic alternatives for patients. This also demonstrates the current trend of increasing collaborations which is expected to aid CAR T-cell therapy market growth in upcoming years.

 

In November 2023, Kite and Arcellx , announced the expansion of their existing partnership, which constituted the development and commercialisation of CART-ddBCMA for relapsed or refractory multiple myeloma. As per the renewal of their agreement, the collaboration will now include lymphomas as well. The candidate is currently under phase 2 clinical development and been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the FDA as well.

 

Growth in Research Activities to Boost the CAR T-cell Therapy Market Size

With rising technical advancements and deeper understanding of genetics, there has been significant development in CAR-T cell therapies trials. In August 2023, Cellectis provided an update on their ongoing three clinical trials and their evaluation. UCART123, an allogenic CAR-T therapy which targets CD123, occurring in patients with relapsed acute myeloid leukaemia (AML), demonstrated improved anti-tumour activity by sustained lymphodepletion and higher UCART123 cell expansion.

 

Technical Advancements Fuel a Surge in Approvals

In December 2023, the FDA approved Kite’s Yescarta ® (axicabtagene ciloleucel) CAR T-cell therapy label update. It is the first and only treatment to showcase overall improved survival data for patients with refractory large B-cell lymphoma. The approval is based on the results from ZUMA-7 study which indicated a 27.4% reduction in the death risk when compared to second of care.

 

In November 2023, Immix Biopharma, Inc. IMMX also revealed that they had received the FDA approval for their new investigational drug which helps the application of NEXICART-2 (NCT06097832) on clinical studies for treatment of relapsed AL amyloidosis. The growth in approvals by the regulatory authorities display a significant CAR T-cell therapy market trend which is projected to help in the market growth in upcoming years.

 

car t-cell therapy market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global CAR T-Cell Therapy Market Segmentation

Market Breakup by Drug Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleuce
  • Idecabtagene Vicleucel
  • Ciltacabtegene Autoleucel
  • Others

 

Market Breakup by Antigen

  • CD19
  • BCMA
  • HER2
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • CLDN18

 

Market Breakup by Application

  • Acute Lymphocytic Leukemia

  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global CAR T-Cell Therapy Market Regional Analysis

The United States is expected to lead the CAR T-cell therapy market share in the forecast period. This can be attributed to an increased emphasis on providing customised patient care solutions. The rising prevalence of cancer along with existence of key healthcare companies plays a pivotal role in the market growth. The surge in research and development activities is a major element as well.

 

In the forecast period, Asia Pacific is expected to witness a significant surge in the market value, with countries like India, China and Japan being a centre of attraction. India is expected to grow owing to increasing healthcare infrastructure development and rise in the foreign investments. In October 2023, Immunoadoptive Cell Therapy (ImmunoACT), an IIT Bombay incubated company received the Central Drugs Standard Control Organisation’s (CDSO) marketing authorisation for the first humanised CD19-targeted CAR T-cell therapy product in India. This showcases that the market is expected to emerge significantly in the upcoming years.

 

car t-cell therapy market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global CAR T-Cell Therapy Market: Competitor Landscape

In July 2023, Pfizer invested USD 25 million equity investment in Caribou Biosciences to develop and extensive allogeneic CAR-T cell therapy for multiple myeloma. The United States based biotech company will invest the money into CB-011, its allogeneic CAR-T cell therapy, which is being studied in a phase 1 clinical trial in patients. It targets the B-cell maturation antigen and is intended to remove the B2M protein and insert a B2M-HLA-E fusion protein to inhibit immune-mediated rejection.

 

In December 2023, FUJIFILM also announced their USD 200 million investment in cell therapies. This investment is intended to strengthen the company’s manufacturing capacity to support iPSC-derived cell therapies, as well as chimeric antigen receptor (CAR), T-cell receptor (TCR), cytoxic T lymphocyte (CTL), natural killer (NK) and tissue-derived therapies. The rising investments and portfolio expansions demonstrate a generic market trend wherein several companies are stepping in to solidify their presence in the market.

 

The key features of the CAR T-cell therapy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Autolus Therapeutics
  • CARsgen Therapeutics Co.Ltd.
  • Juno Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • Bluebird bio, Inc.
  • CELGENE CORPORATION
  • Eureka Therapeutics Inc.
  • Avacta Life Sciences Ltd.
  • Calyxt Inc.
  • Celyad Oncology SA
  • Fortress Biotech, Inc
  • IMMUNE THERAPEUTICS, INC
  • Alaunos Therapeutics, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Antigen
  • Application
  • Region
Breakup by Drug Type
  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleuce
  • Idecabtagene Vicleucel
  • Ciltacabtegene Autoleucel
  • Others
Breakup by Antigen
  • CD19
  • BCMA
  • HER2
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • CLDN18
Breakup by Application
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Autolus Therapeutics
  • CARsgen Therapeutics Co.Ltd.
  • Juno Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • Bluebird bio, Inc.
  • CELGENE CORPORATION
  • Eureka Therapeutics Inc.
  • Avacta Life Sciences Ltd.
  • Calyxt Inc.
  • Celyad Oncology SA
  • Fortress Biotech, Inc
  • IMMUNE THERAPEUTICS, INC
  • Alaunos Therapeutics, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global CAR T-Cell Therapy Market Overview 

    3.1    Global CAR T-Cell Therapy Market Historical Value (2017-2023) 
    3.2    Global CAR T-Cell Therapy Market Forecast Value (2024-2032)
4    Global CAR T-Cell Therapy Market Landscape
    4.1    Global CAR T-Cell Therapy Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global CAR T-Cell Therapy Product Landscape
        4.2.1    Analysis by Drug Type
        4.2.2    Analysis by Antigen Type
        4.2.3    Analysis by Application
5    Global CAR T-Cell Therapy Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global CAR T-Cell Therapy Market Segmentation 
    6.1    Global CAR T-Cell Therapy Market by Drug Type
        6.1.1    Market Overview 
        6.1.2    Axicabtagene Ciloleucel
        6.1.3    Tisagenlecleucel
        6.1.4    Brexucabtagene Autoleucel
        6.1.5    Lisocabtagene Maraleuce
        6.1.6    Idecabtagene Vicleucel
        6.1.7    Ciltacabtegene Autoleucel
        6.1.8    Others
    6.2    Global CAR T-Cell Therapy Market by Antigen
        6.2.1    Market Overview
        6.2.2    CD19
        6.2.3    BCMA
        6.2.4    HER2
        6.2.5    GD2
        6.2.6    CD22
        6.2.7    CD30
        6.2.8    CD33
        6.2.9    HER1
        6.2.10    CLDN18
    6.3    Global CAR T-Cell Therapy Market by Application
        6.3.1    Market Overview
        6.3.2    Acute Lymphocytic Leukemia
        6.3.3    Chronic Lymphocytic Leukemia
        6.3.4    Diffuse Large B-Cell Lymphoma (DLBCL)
        6.3.5    Follicular Lymphoma
        6.3.6    Mantle Cell Lymphoma
        6.3.7    Multiple Myeloma
        6.3.8    Glioblastoma
        6.3.9    Sarcoma
        6.3.10    Neuroblastoma
        6.3.11    Acute Myeloid Leukemia
        6.3.12    Breast Cancer
        6.3.13    Pancreatic Cancer
        6.3.14    Hepatocellular Carcinoma
        6.3.15    Colorectal Cancer
        6.3.16    Others
    6.4    Global CAR T-Cell Therapy Market by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America CAR T-Cell Therapy Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe CAR T-Cell Therapy Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific CAR T-Cell Therapy Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Others
10    Latin America CAR T-Cell Therapy Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa CAR T-Cell Therapy Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by Year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding & Investment Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Autolus Therapeutics
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    CARsgen Therapeutics Co.Ltd.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Juno Therapeutics, Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Sorrento Therapeutics, Inc.
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Bluebird bio, Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    CELGENE CORPORATION
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Eureka Therapeutics Inc.
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Avacta Life Sciences Ltd.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Calyxt Inc.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Celyad Oncology SA
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Fortress Biotech, Inc
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    IMMUNE THERAPEUTICS, INC
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Alaunos Therapeutics, Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Novartis AG
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Gilead Sciences, Inc.
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
18    Global CAR T-Cell Therapy Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 2.5 billion in 2023, driven by the growing prevalence of cancer across the globe.

The market is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032, likely to reach a market value of USD 9 billion by 2032.

The market demand is driven by the rising emphasis on offering personalised treatment to the patients, along with technical advancements and a surge in research and development activities, owing to a better understanding of genetics and cellular biology.

The major market trend involves increasing partnerships and collaborations between influential market players. For instance, In December 2023, AbelZeta and AstraZeneca entered an agreement to develop C-CAR031, an autologous and armoured GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy designed to treat hepatocellular carcinoma (HCC).

Based on drug types, the market is divided into Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleuce, Idecabtagene Vicleucel, Ciltacabtegene Autoleucel, and others.

CD19, BCMA, HER2, GD2, CD22, CD30, CD33, HER1 and CLDN18 are common antigens available in the market.

Common application areas include acute lymphocytic leukemia, chronic lymphocytic leukemia, diffuse large B-Cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, glioblastoma, sarcoma, neuroblastoma, acute myeloid leukemia, breast cancer, pancreatic cancer, hepatocellular carcinoma, and colorectal cancer, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.

Key players involved in the market are Autolus Therapeutics, CARsgen Therapeutics Co.Ltd., Juno Therapeutics, Inc., Sorrento Therapeutics, Inc., Bluebird bio, Inc., CELGENE CORPORATION, Eureka Therapeutics Inc., Avacta Life Sciences Ltd., Calyxt Inc., Celyad Oncology SA, Fortress Biotech, Inc., IMMUNE THERAPEUTICS, INC., Alaunos Therapeutics, Inc., Gilead Sciences, Inc., and Novartis AG.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER